Clinical trial
Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane…
NCT00040014 · Pfizer, Industry · Terminated
Key facts
| NCT number | NCT00040014 |
|---|---|
| Title | Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women |
| Official title | Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women With Advanced Breast Cancer Having Progressed on Tamoxifen. |
| Lead sponsor | Pfizer, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | exemestane |
| Enrollment | 100 |
| Start date | Jun 1, 2002 |
| Primary completion | Dec 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Jun 20, 2002 |
| Last update posted | Feb 16, 2012 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: